A high rate of incorrect biopsies has tangled the mid-stage results for Nymox Pharmaceutical’s experimental prostate cancer drug. Investigators say that NX-1207 reduced the rate of disease progression in patients, but they couldn’t determine if the drug hits its primary endpoint due to “the high percentage of false negative repeat biopsies in the active surveillance […]
Expecting to improve its odds of success for the experimental heart drug darapladib, a top drug prospect that failed its first late-stage test, investigators at GlaxoSmithKline have changed up the primary endpoint in the remaining Phase III study that reads out later this quarter. …read more Source: GlaxoSmithKline ups odds on heart drug hopeful with […]
Late last year, Sanofi’s MS drug Lemtrada was slapped down by the FDA. Sanofi investigators now tell FierceBiotech that two years after patients in Phase III studies received their last course of treatment, many are still clearly benefiting from the drug. …read more Source: Sanofi’s MS team rebuilds its case for the FDA-rejected MS drug […]
Regeneron R&D chief George Yancopoulos suffered a major drop in compensation last year–but he’s still likely to retain his title as the highest paid research chief in the global industry. …read more Source: Regeneron R&D chief’s compensation shrinks, but still tops the chart
San Diego’s Otonomy has hauled in another $49 million to advance its therapies for ear disorders, hoping to do for hearing-robbing ailments what VEGF inhibitors did for eye diseases. …read more Source: Otonomy pockets $49M to hit the gas on its ear treatments
After a quick march through the clinic, Novartis has won early FDA approval for the new “breakthrough” lung cancer drug ceritinib (or LDK378), which will now be launched as Zykadia. …read more Source: Novartis grabs early FDA approval of lung cancer drug Zykadia
France’s Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But the CEO says he’s laying the groundwork for a late-stage study, confident that he can find another partner. …read more Source: Transgene takes a hit as Novartis shreds […]
Allergan is keeping the M&A plates spinning amid Big Pharma’s big embrace of megadeals, reportedly reaching out to potential suitors Sanofi and Johnson & Johnson while gearing up to make another pass at acquiring Shire. …read more Source: Allergan woos J&J, Sanofi while keeping its eyes on Shire, per reports
Late last week, shares of CytoKinetics tanked when it put out the word that its lead drug for Lou Gehrig’s disease had missed the primary endpoint. Today, the biotech added that the ALS drug also missed a string of secondary endpoints, as well. There was, though, one bright spot: The drug achieved the secondary endpoint […]
Now that Pfizer has gone ahead with its $100 billion bid for AstraZeneca, the big question on everyone’s mind is, why would they do it? …read more Source: Why would Pfizer want to buy AstraZeneca? It’s not R&D
